

1 **Aging dampens the intestinal innate immune response during *Clostridioides difficile***  
2 **infection and is associated with altered intestinal eosinophil mobilization**

3

4 Lisa Abernathy-Close<sup>a</sup>, Michael G. Dieterle<sup>b,c</sup>, Kimberly C. Vendrov<sup>a</sup>, Ingrid L. Bergin<sup>d</sup>, Vincent  
5 B. Young<sup>a,c#</sup>

6

7 <sup>a</sup>Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann  
8 Arbor, MI, USA

9 <sup>b</sup>Medical Scientist Training Program, University of Michigan, Ann Arbor, MI, USA.

10 <sup>c</sup>Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA

11 <sup>d</sup>Unit for Laboratory Animal Medicine; University of Michigan; Ann Arbor, MI, USA

12

13 **Running title:** Aging alters innate immunity in intestinal infection

14

15 #Address correspondence to Vincent B. Young, [youngvi@umich.edu](mailto:youngvi@umich.edu)

16 **ABSTRACT**

17

18 *Clostridioides* (formerly *Clostridium*) *difficile* is the most common cause of hospital-  
19 acquired infection, and advanced age is a risk factor for *C. difficile* infection. Disruption of the  
20 intestinal microbiota and immune responses contribute to host susceptibility and severity of *C.*  
21 *difficile* infection. However, the impact of aging on the cellular immune response associated with  
22 *C. difficile* infection in the setting of advanced age remains to be well described. This study  
23 explores the effect of age on cellular immune responses in *C. difficile* infection as well as  
24 disease severity. Young adult mice (2-3 months old) and aged mice (22-28 months old) were  
25 rendered susceptible to *C. difficile* infection with cefoperazone and then infected with *C. difficile*  
26 strains of varying disease-causing potential. Aged mice infected with *C. difficile* develop more  
27 severe clinical disease, compared to young mice. Tissue-specific CD45+ immune cell  
28 responses occurred at the time of peak disease severity in the cecum and colon of all mice  
29 infected with a high-virulence strain of *C. difficile*; however, significant deficits in intestinal  
30 neutrophils and eosinophils were detected in aged mice. Interestingly, while *C. difficile* infection  
31 in young mice was associated with a robust increase in cecal and colonic eosinophils, there was  
32 a complete lack of an intestinal eosinophil response in aged counterparts accompanied by a  
33 simultaneous increase in blood eosinophils with severe disease. These findings demonstrate  
34 that age-related alterations in immune responses are associated with significantly worse *C.*  
35 *difficile* infection and support a key role for intestinal eosinophils in mitigating *C. difficile*-  
36 mediated disease severity.

37 **INTRODUCTION**

38

39 In the last two decades, the frequency of *C. difficile* infection (CDI) among hospitalized  
40 patients has steadily increased, particularly among those 65 years of age and older (1). Several  
41 studies have demonstrated that as an individual's age increases, so does their risk of *C. difficile*  
42 infection and the severity of CDI-associated disease (2, 3). While the connection between  
43 advanced age and severe CDI disease outcomes has been well established, the contribution of  
44 the aging host's immune responses during acute CDI disease development and pathogenicity of  
45 *C. difficile* strain remains to be clarified.

46 Recently, peripheral eosinophil counts were found to be predictive of CDI disease  
47 severity and mortality in patients (4), and eosinophils were shown to potentially be protective in  
48 mouse models of CDI (5, 6). Eosinophils are innate immune cells that predominantly reside in  
49 close proximity to microbes that colonize mucosal surfaces under non-inflammatory  
50 homeostasis (7). The biological function of eosinophils in health and disease are most well  
51 studied and described in the protection against helminth infections (8) and in the pathogenesis  
52 of allergy (9). There is now growing evidence supporting a previously under-appreciated role for  
53 eosinophils as important mediators of intestinal immune responses (10), and the expression of a  
54 broad range of pattern-recognition receptors in eosinophils suggest a potential role in bacterial  
55 infection (11). Recent efforts by multiple research groups have indicated a role for eosinophils in  
56 CDI disease (4-6). However, the specific role for eosinophils in CDI disease severity has yet to  
57 be completely elucidated, and few studies characterize the innate immune responses to *C.*  
58 *difficile* strains with a range of virulence potential in animals of advanced age.

59 CDI disease severity depends on host factors and virulence of the *C. difficile* strain (12).  
60 Aging is known to cause immune dysfunction and negatively impacts patients in the setting of  
61 infectious diseases in the intestine (13). While immunosenescence likely plays a role in  
62 modulating CDI outcomes (14, 15), dysregulation of particular immune cell subsets may

63 differentially contribute to CDI disease severity. In the present study, we characterize the effect  
64 of *C. difficile* strain virulence and host age on the cellular immune response using a murine  
65 model of CDI utilizing *C. difficile* strain VPI 10463 (high-virulence) and strain 630 (low-  
66 virulence), as well as a young cohort and an aged cohort of adult mice reared in the same  
67 animal facility.

68

69

## 70 **MATERIALS AND METHODS**

71

72 **Mice.** Male and female specific pathogen-free (SPF) C57BL/6 wild-type adult mice that were  
73 young (2-3 months old) or aged (22-28 months old) were used in these studies. These mice  
74 were from a breeding colony at the University of Michigan that were originally derived from  
75 Jackson Laboratories over a decade ago. Euthanasia was carried out via CO<sub>2</sub> inhalation at the  
76 conclusion of the experiment. Animal studies were approved by the Institutional Animal Care &  
77 Use Committee (IACUC) at the University of Michigan and animal husbandry was performed in  
78 an AAALAC-accredited facility.

79

80 ***C. difficile* strains and growth conditions.** The *C. difficile* strains used in this study include  
81 reference strain VPI 10463 (ATCC 43255) and strain 630 (ATCC BAA-1382), and have been  
82 previously described in a murine model of CDI by Theriot *et al.* (12).

83

84 **Antibiotic administration and infection with *C. difficile*.** Mice were rendered susceptible to  
85 *C. difficile* infection by placing mice on 0.5 mg/mL cefoperazone (MP Pharmaceuticals) in sterile  
86 distilled drinking water (Gibco) ad libitum. The antibiotic-supplemented water was provided for  
87 10 days, followed by 2 days of drinking water without antibiotics. Animals were then inoculated  
88 by oral gavage with 10<sup>3</sup>-10<sup>4</sup> CFUs of *C. difficile* spores suspended in 20-100 µl of distilled water

89 (Gibco) or mock-infected with vehicle alone. Viable spores in each inoculum was enumerated by  
90 plating for colony-forming units (CFU) per mL on pre-reduced taurocholate cycloserine cefoxitin  
91 fructose agar (TCCFA). TCCFA was prepared as originally described (16) with modifications.  
92 Briefly, the agar base consisted of 40 g of Proteose Peptone No. 3 (BD Biosciences), 5 g of  
93 Na<sub>2</sub>HPO<sub>4</sub> (Sigma-Aldrich), 1 g of KH<sub>2</sub>PO<sub>4</sub> (Fisher), 2 g NaCl (J.T. Baker), 0.1 g MgSO<sub>4</sub>  
94 (Sigma), 6 g fructose (Fisher), and 20 g of agar (Life Technologies) dissolved in 1L of Milli-Q  
95 water. The prepared medium was autoclaved and supplemented with a final concentration of  
96 250 µg/mL D-cycloserine (Sigma-Aldrich), 16 µg/mL cefoxitin (Sigma-Aldrich), and 0.1%  
97 taurocholate (Sigma). Over the course of the experiment, mice were regularly weighed and  
98 cecal contents were collected for quantitative culture.

99

100 **C. difficile quantification.** Cecal contents were collected in a pre-weighed sterile tube from  
101 each mouse at time of euthanasia. Immediately following collection, the tubes were re-weighed  
102 to determine fecal weight and passed into an anaerobic chamber (Coy Laboratories). Each  
103 sample was then diluted 10% (w/v) with pre-reduced sterile PBS and serially diluted onto pre-  
104 reduced TCCFA plates with or without erythromycin supplementation. *C. difficile* strain 630 is  
105 erythromycin-resistant, whereas *C. difficile* strain VPI 10463 is sensitive to erythromycin. The  
106 plates were incubated anaerobically at 37°C, and colonies were enumerated after 18 to 24  
107 hours of incubation.

108

109 **Clinical disease severity scoring.** Mice were monitored for clinical signs of disease. Disease  
110 scores were averaged based on scoring of the following features for signs of disease: weight  
111 loss, activity, posture, coat, diarrhea, eyes/nose. A 4-point scale was assigned to score each  
112 feature and the sum of these scores determined the clinical disease severity score (17).

113

114 **Lamina propria cell isolation.** Cecum and colon were excised, separated, and the lumen was  
115 flushed. Residual fat was removed and tissues were opened longitudinally. Tissue was placed  
116 in pre-warm RPMI medium containing 0.5M EDTA, dithiothreitol, and fetal bovine serum (FBS)  
117 and incubated at 37°C on an orbital shaker at 150 rpm for 15 min. After incubation, a steel  
118 strainer was used to separate tissue pieces from the epithelium-containing supernatant. Tissue  
119 was minced in RPMI medium containing dispase, collagenase II, DNase I, and FBS and  
120 incubated at 37°C on an orbital shaker at 150 rpm for 30 min. Digested tissue was filtered  
121 through a 100 µm cell strainer followed by a 40 µm cell strainer. The resultant single cell  
122 suspensions were counted on a hemocytometer using trypan blue exclusion test.

123

124 **Flow cytometry.** Lamina propria single-cell suspensions from colon or cecum were incubated  
125 with anti-CD16/32 to reduce non-specific binding. Cells were incubated on ice for 30 mins in the  
126 dark, with a cocktail of fluorescent antibodies consisting of anti-CD45.2 PerCP-Cy5 (clone: 104),  
127 CD3 PE (clone: 145-2C11), CD11b PE-eFluor 610 (clone: M1/70), CD11c Alexa Fluor 700  
128 (clone: N418), Ly6G PE-Cy7 (clone: 1A8), and Siglec-F Alexa Fluor 647 (clone: E50-2440). All  
129 antibodies were purchased from eBioscience, Biolegend, or BD Biosciences. Stained cells were  
130 incubated with an eFluor 450 fixable viability dye (eBioscience) and fixed with 0.5%  
131 paraformaldehyde. Cells were acquired using a BD LSRFortessa X-20 flow cytometer (BD  
132 Biosciences, San Jose, CA) and analyzed on FlowJo v10 software (Tree Star Inc., Ashland,  
133 OR).

134

135 **Eosinophil enumeration in blood.** Blood was collected via cardiac puncture in microtainer  
136 tubes with K<sub>2</sub> EDTA (Sarstedt, Nümbrecht, Germany) at the experimental endpoint. Blood  
137 samples were taken immediately to the Unit for Laboratory Animal Medicine In-Vivo Animal  
138 Core and processed for a complete blood count on an automated hematology analyzer  
139 (Hemavet 950, Drew Scientific, Miami Lakes, FL).

140

141 **Statistics.** One-way analysis of variance (ANOVA) with Tukey's post-hoc test was performed  
142 using R for *C. difficile* burden and cell population analyses. Clinical scores were analyzed in  
143 python using a Kruskal-Wallis one-way ANOVA with Bonferroni post-hoc test. A p-value greater  
144  $p < 0.05$  was considered statistically significant.

145

146

## 147 **RESULTS**

148

### 149 ***Aged mice infected with a high-virulence strain of C. difficile develop more severe*** 150 ***clinical disease compared to young mice***

151

152 Young mice (2-3 months old) and aged mice (22-28 months old) were rendered  
153 susceptible to *C. difficile* infection (CDI) by treatment with the antibiotic cefoparazone prior to  
154 oral inoculation with spores derived from *C. difficile* strain 630 (low virulence) or strain VPI  
155 10463 (high virulence) (Figure 1A). There was no age or strain-associated difference in *C.*  
156 *difficile* colonization (Figure 1B). At the time of peak clinical disease, *C. difficile* strain VPI 10463  
157 causes significantly more severe disease in both young and aged mice, compared to infection  
158 with *C. difficile* strain 630 (Figure 1C,  $p < 0.0001$ ).

159

### 160 ***Infection with C. difficile strain VPI 10463, but not strain 630, results in robust cellular*** 161 ***immune response in cecum and colon of mice, regardless of animal age***

162

163 Total immune cells and myeloid cells subsets in the lamina propria of cecum and colon  
164 from young and aged mice were analyzed by flow cytometry at the time of peak disease severity  
165 (representative plots, Figure 2A and 2D). *C. difficile* strain 630 did not elicit an early cellular

166 intestinal immune response in the cecum (Figure 2B and 2C) or colon (Figure 2E and 2F),  
167 independent of age. Due to the absence of a local intestinal cellular immune response during  
168 infection with the low-virulence *C. difficile* strain 630, we focused on further characterizing the  
169 nature of the immune cells infiltrating the distal intestinal tract during infection with the more  
170 virulent *C. difficile* strain VPI 10463.

171  
172 ***Aged mice mount reduced neutrophil and eosinophil responses in the distal intestine***  
173 ***during severe C. difficile infection compared to young mice***

174  
175 Of the CD45+ immune cells in the cecum and colon young and aged mice infected with  
176 *C. difficile* strain VPI 10463 at the time of peak disease severity, the majority are CD11b+ cells  
177 (Figure 3A and 3B). While there is a significant increase in CD11b+ cell numbers in the cecum  
178 of young ( $p < 0.0001$ ) and aged mice ( $p < 0.01$ ) infected with *C. difficile* VPI 10463, this  
179 response is significantly blunted in aged mice (Figure 3C and 3D,  $p < 0.0001$ ). Interestingly, we  
180 observed local differences in intestinal CD11b+ cell responses in aged mice. There was a lack  
181 of response by CD11b+ cells in the colon of aged mice infected with *C. difficile* VPI 10463, in  
182 contrast to a significant increase in colonic CD11b+ cells in young counterparts (Figure 3E and  
183 3F). Similarly, subsets of CD11b+ myeloid cells including CD11b+Ly6G+Siglec-F- neutrophils  
184 and CD11b+Ly6G-Siglec-F+ eosinophils showed an age-dependent difference in intestinal  
185 response to *C. difficile* infection (Figure 4). While aged mice indeed mount a cecal neutrophil  
186 response during severe CDI, it is significantly dampened compared to their young counterparts  
187 (Figure 4C,  $p < 0.01$ ). Furthermore, colonic neutrophil infiltration during CDI is not observed in  
188 aged mice during severe CDI (Figure 4C).

189

190



191 ***Differential intestinal and systemic eosinophil cellular response during severe C. difficile***  
192 ***infection in aged mice***

193

194         Since it has been suggested that eosinophils play a protective role in CDI using a mouse  
195 model of *C. difficile* infection (5), we hypothesized that eosinophil responses in older animals  
196 during *C. difficile* infection would differ significantly compared to their relatively young  
197 counterparts. Young mice at the time of peak CDI disease severity mounted a robust cecal and  
198 colonic eosinophil cellular response; however, intestinal eosinophil infiltration during peak CDI  
199 disease severity is absent in aged mice infected with *C. difficile* strain VPI 10463 (Figure 4D).  
200 We sought to determine if there was an age-related difference in peripheral eosinophil  
201 responses during *C. difficile* infection. We found that aged mice infected with the high-virulence  
202 *C. difficile* strain VPI 10463 respond with increased eosinophil to total leukocyte ratio (Figure  
203 5A,  $p < 0.05$ ) compared to young mice infected with the same strain of *C. difficile*. Although  
204 there is a complete lack of local eosinophil infiltration in the distal intestine of aged mice with  
205 severe CDI, there is a concomitant significant increase in the absolute number of peripheral  
206 eosinophils in the blood of aged mice infected with *C. difficile* strain VPI 10463 compared to  
207 their young counterparts (Figure 5B,  $p < 0.01$ ). In contrast, young mice do not demonstrate a  
208 change in peripheral blood eosinophil levels at the peak of CDI severity, regardless of infecting  
209 *C. difficile* strain (Figure 5B). Interestingly, while severe CDI was associated with increased  
210 blood eosinophil numbers in aged mice, this was not observed with less severe CDI associated  
211 with *C. difficile* strain 630.

212 **DISCUSSION**

213

214           Although advanced age is a risk factor for *C. difficile* infection (CDI) (1), the relationship  
215 between the aging immune system and *C. difficile* infection is not well known. This study  
216 demonstrates an overall decrease in intestinal innate immune responses during acute *C. difficile*  
217 infection in mice with advanced age, and identifies a specific aging-related defect in eosinophil  
218 responses during CDI. We show that aged mice (22 – 24 months old) develop more severe CDI  
219 disease and mount a significantly blunted intestinal cellular immune response compared to  
220 young mice (2 – 3 months old), with a notable absence of an intestinal eosinophil response.  
221 Interestingly, aged mice had a significant peripheral eosinophil response whereas young mice  
222 lacked an eosinophil increase detected in the blood during severe CDI. Our results also suggest  
223 that eosinophils may play differential roles, whether that be protective or pathogenic.  
224 Additionally, eosinophil counts may predict different disease outcomes during *C. difficile*  
225 infection depending on their location in intestinal tissue or circulation in the periphery. In the  
226 present study, we characterized the intestinal cellular immune response to *C. difficile* infection  
227 during peak disease severity in young and aged mice, with a focus on myeloid cell subsets  
228 mobilized during the innate immune response.

229           Peniche *et al.* showed that middle-aged mice (12 – 14 months old) have increased  
230 susceptibility to *C. difficile* infection and worse CDI disease, compared to young controls (18).  
231 They report that this observation was driven by impaired innate immune responses; however,  
232 eosinophils were not evaluated in this study. Our data showing a decreased intestinal neutrophil  
233 response in aged mice infected with *C. difficile* agrees with a recent study that examined the  
234 effect of age on *C. difficile* infection in a mouse model (15).

235           Little is known about the relationship between CDI and eosinophils. One study  
236 demonstrated that *C. difficile* toxin suppresses a host protective colonic eosinophil responses in  
237 a toll-like receptor 2 (TLR2) dependent manner (6). Recently, Buonomo *et al.* reported that an

238 increase in intestinal eosinophils was associated with reduced host mortality during *C. difficile*  
239 infection (5). In the aforementioned study, cytokine, IgA and IgG, and *muc2* analysis were  
240 assessed in the cecum while eosinophils were enumerated in the colon. While we detected  
241 robust eosinophil infiltration in the cecum of young mice, we did not observe this in the colon of  
242 young or aged animals. Another group found that peripheral loss of eosinophils in patients with  
243 *C. difficile* infection was predictive of severe disease (4). We report that young mice had  
244 significantly increased numbers of intestinal eosinophils during *C. difficile* infection, compared to  
245 mock-infected young controls, while aged mice did not have intestinal eosinophil infiltration and  
246 significantly worse CDI disease, compared to young mice. However, eosinophils in the blood of  
247 aged mice infected with the more virulent strain of *C. difficile* were significantly increased at the  
248 time of peak CDI disease severity, compared to young counterparts. It is possible that  
249 eosinopenia at the time of symptom onset is predictive of increased CDI disease severity and  
250 mortality, but eosinophil levels may increase in the blood as CDI disease progresses over time.  
251 Additionally, eosinophil responses may be altered in older patient populations and may not be  
252 predictive of CDI outcomes. Our results also suggest tissue-specific eosinophil responses in the  
253 distal intestinal tract, so further examination of local tissue responses is warranted.

254 While the general blunted cellular immune response in the intestine of aged mice with  
255 CDI may be explained by immunosenescence, which describes the aging of the immune  
256 system, the observed age-related inverse of eosinophil responses to acute CDI suggests that  
257 this immune cell population plays a role in CDI pathology. Aged mice had significantly more  
258 severe clinical disease, compared to their younger counterparts. Young animals have a robust  
259 cellular intestinal immune response during acute CDI, whereas aged mice respond to *C. difficile*  
260 infection with intestinal eosinopenia and concomitant peripheral eosinophilia. These data  
261 suggest a role for eosinophils in age-associated CDI outcomes in older patient populations.

262

263 **FIGURE LEGENDS**

264

265 **Figure 1. *C. difficile* infection with strain VPI 10463 or strain 630 results in increased**  
266 **disease severity in aged mice, compared to young mice.** A) Mouse model of *C. difficile*  
267 infection in young and aged animals. B) Cecal contents were collected from young mice and  
268 aged mice at experimental endpoint (day 2 post-infection with strain VPI 10463 or day 4 post  
269 infection with strain 630) and plated anaerobically on selective agar plates to quantify *C. difficile*  
270 burden. Dotted line indicates limit of detection for *C. difficile* quantification ( $10^3$  CFU). C) Clinical  
271 scores of young and aged mice infected with *C. difficile* strain VPI 10463 or strain 630 at peak  
272 clinical disease severity (day 2 and 4 post-infection, respectively). One-way ANOVA with  
273 Tukey's post-hoc test was performed for *C. difficile* burden analysis and clinical scores were  
274 analyzed using a Kruskal-Wallis one-way ANOVA with Bonferroni post-hoc test, \* $p < 0.05$ ; \*\*\* $p$   
275  $< 0.001$ .

276

277 **Figure 2. CD45+ leukocytes are preferentially increased in the cecum and colon lamina**  
278 **propria of young and aged mice infected with *C. difficile* strain VPI 10463, compared to**  
279 **infection with *C. difficile* strain 630.** A) Representative flow cytometry plots indicating the  
280 percentage of CD45+ leukocytes in cecum lamina propria. B) Percentage and C) absolute  
281 number of CD45+ leukocytes in total live lamina propria cells harvested from cecum. D)  
282 Representative flow cytometry plots indicating the percentage of CD45+ leukocytes in colon  
283 lamina propria. E) Percentage and F) absolute number of CD45+ leukocytes in total live lamina  
284 propria cells harvested from colon. ANOVA and Tukey test \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ;  
285 \*\*\*\* $p < 0.0001$ .

286

287 **Figure 3. CD11b+ cells are the dominant immune cell type in the cecum and colon lamina**  
288 **propria of young and aged infected with *C. difficile* strain VPI 10463.** Mock-infected or *C.*  
289 *difficile* strain VPI 10463-infected young and aged mice 2 days post-infection analyzed by flow

290 cytometry for immune cell subsets. The ratio of CD11b+ cells, CD3+ lymphocytes, and “other”  
291 CD11b-CD3- cells of the total CD45+ immune cells in A) cecum and B) colon of mock or *C.*  
292 *difficile* strain VPI 10463-infected young and aged mice 2 days post-infection. C) Representative  
293 flow cytometry plots indicating the percentage of CD11b+ myeloid cells in colon lamina propria.  
294 D) Absolute number of CD11b+ cells determined by flow cytometry in cecum. E) Representative  
295 flow cytometry plots indicating the percentage of CD11b+ cells in colon lamina propria. F)  
296 Absolute number of CD11b+ cells determined by flow cytometry in colon. ANOVA and Tukey  
297 test \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ .

298

299 **Figure 4. Neutrophil and eosinophil cellular infiltration in the distal intestine is**  
300 **significantly decreased in aged mice infected with *C. difficile* strain VPI 10463, compared**  
301 **to young counterparts.** Mock-infected or *C. difficile* strain VPI 10463-infected young and aged  
302 mice 2 days post-infection analyzed by flow cytometry for CD11b+Ly6G+Siglec-F- neutrophils  
303 and CD11b+Ly6G-Siglec-F+ eosinophils. Representative flow cytometry plots indicating the  
304 percentage of CD11b+Ly6G+Siglec-F- neutrophils and CD11b+Ly6G-Siglec-F+ eosinophils in  
305 A) cecum and B) colon lamina propria. C) Absolute numbers of neutrophils in the cecum and  
306 colon lamina propria. D) Absolute eosinophil number in cecum and colon lamina propria.  
307 ANOVA and Tukey test \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ .

308

309 **Figure 5. Infection with *C. difficile* strain VPI 10463 results in differential systemic**  
310 **eosinophil responses in aged mice, compared to young mice.** A) Percentage of eosinophils  
311 of total white blood cells in young and aged mice at baseline or at peak CDI disease severity. B)  
312 Absolute numbers of eosinophils in the blood of young and aged mice at baseline or infected  
313 with *C. difficile* strain 630 or strain VPI 10463. ANOVA and Tukey test \* $p < 0.05$ ; \*\* $p < 0.01$ ;  
314 \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ .

315

316 **ACKNOWLEDGMENTS**

317

318           We thank Naomi Perlman and James M. George for their assistance in the laboratory,  
319 which facilitated conducting these experiments. We thank Anna Colvig and Florin Timpau of the  
320 ULAM In Vivo Animal Core for hematology assessment. This study was funded by grant  
321 U01AI12455 awarded to V.B.Y. by the National Institute of Allergy and Infectious Diseases at  
322 the National Institutes of Health. In addition, M.G.D. was supported by NIH grant  
323 T32GM007863. The funding agencies had no role in study design, data collection and  
324 interpretation, or the decision to submit the work for publication.

325

326 **REFERENCES**

327

328 1. Leffler DA, Lamont JT. 2015. Clostridium difficile infection. N Engl J Med 372:1539-48.

329 2. Carignan A, Allard C, Pépin J, Cossette B, Nault V, Valiquette L. 2008. Risk of  
330 Clostridium difficile infection after perioperative antibacterial prophylaxis before and  
331 during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis 46:1838-43.

332 3. Lessa FC, Gould CV, McDonald LC. 2012. Current status of Clostridium difficile infection  
333 epidemiology. Clin Infect Dis 55 Suppl 2:S65-70.

334 4. Kulaylat AS, Buonomo EL, Scully KW, Hollenbeak CS, Cook H, Petri WA, Stewart DB.  
335 2018. Development and Validation of a Prediction Model for Mortality and Adverse  
336 Outcomes Among Patients With Peripheral Eosinopenia on Admission for Clostridium  
337 difficile Infection. JAMA Surg.

338 5. Buonomo EL, Cowardin CA, Wilson MG, Saleh MM, Pramoongjago P, Petri WA. 2016.  
339 Microbiota-Regulated IL-25 Increases Eosinophil Number to Provide Protection during  
340 Clostridium difficile Infection. Cell Rep 16:432-443.

341 6. Cowardin CA, Buonomo EL, Saleh MM, Wilson MG, Burgess SL, Kuehne SA, Schwan  
342 C, Eichhoff AM, Koch-Nolte F, Lyras D, Aktories K, Minton NP, Petri WA. 2016. The  
343 binary toxin CDT enhances Clostridium difficile virulence by suppressing protective  
344 colonic eosinophilia. Nat Microbiol 1:16108.

345 7. Travers J, Rothenberg ME. 2015. Eosinophils in mucosal immune responses. Mucosal  
346 Immunol 8:464-75.

347 8. Huang L, Appleton JA. 2016. Eosinophils in Helminth Infection: Defenders and Dupes.  
348 Trends Parasitol 32:798-807.

349 9. Martin LB, Kita H, Leiferman KM, Gleich GJ. 1996. Eosinophils in allergy: role in  
350 disease, degranulation, and cytokines. Int Arch Allergy Immunol 109:207-15.


- 351 10. Jung Y, Rothenberg ME. 2014. Roles and regulation of gastrointestinal eosinophils in  
352 immunity and disease. *J Immunol* 193:999-1005.
- 353 11. Kvarnhammar AM, Cardell LO. 2012. Pattern-recognition receptors in human  
354 eosinophils. *Immunology* 136:11-20.
- 355 12. Theriot CM, Koumpouras CC, Carlson PE, Bergin, II, Aronoff DM, Young VB. 2011.  
356 Cefoperazone-treated mice as an experimental platform to assess differential virulence  
357 of *Clostridium difficile* strains. *Gut Microbes* 2:326-34.
- 358 13. Mabbott NA, Kobayashi A, Sehgal A, Bradford BM, Pattison M, Donaldson DS. 2015.  
359 Aging and the mucosal immune system in the intestine. *Biogerontology* 16:133-45.
- 360 14. van Opstal E, Kolling GL, Moore JH, Coquery CM, Wade NS, Loo WM, Bolick DT, Shin  
361 JH, Erickson LD, Warren CA. 2016. Vancomycin Treatment Alters Humoral Immunity  
362 and Intestinal Microbiota in an Aged Mouse Model of *Clostridium difficile* Infection. *J*  
363 *Infect Dis* 214:130-9.
- 364 15. Shin JH, Gao Y, Moore JH, Bolick DT, Kolling GL, Wu M, Warren CA. 2018. Innate  
365 Immune Response and Outcome of *Clostridium difficile* Infection Are Dependent on  
366 Fecal Bacterial Composition in the Aged Host. *J Infect Dis* 217:188-197.
- 367 16. George WL, Sutter VL, Citron D, Finegold SM. 1979. Selective and differential medium  
368 for isolation of *Clostridium difficile*. *J Clin Microbiol* 9:214-9.
- 369 17. Warren CA, van Opstal E, Ballard TE, Kennedy A, Wang X, Riggins M, Olekhnovich I,  
370 Warthan M, Kolling GL, Guerrant RL, Macdonald TL, Hoffman PS. 2012. Amixicile, a  
371 novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against  
372 *Clostridium difficile* in a mouse infection model. *Antimicrob Agents Chemother* 56:4103-  
373 11.
- 374 18. Peniche AG, Spinler JK, Boonma P, Savidge TC, Dann SM. 2018. Aging impairs  
375 protective host defenses against *Clostridioides (Clostridium) difficile* infection in mice by  
376 suppressing neutrophil and IL-22 mediated immunity. *Anaerobe* 54:83-91.






# Figure 1


## A









## B




## C




## Figure 2







**A**




**B**



**C**




**D**



## Figure 5

### A



### B

